Personalized stack screening — transporter competition, CYP450 induction, and anticoagulant antagonism across a real-world supplement + prescription regimen
Before any interaction can be flagged, every compound in a regimen must be characterized by how it actually gets into the body: which intestinal transporter it competes for, whether it depends on bile-salt micelle formation, and which hepatic cytochrome P450 (CYP450) isoenzyme metabolizes it or its co-administered drugs. This case stack — five over-the-counter supplements, two fat-soluble vitamins, an herbal anxiolytic, and a prescription anticoagulant — is a deliberately dense, clinically realistic combination of the kind increasingly seen in patients over 50.
Each compound is tagged with its dominant uptake or metabolism pathway — the information layer that every downstream interaction check is built on:
• Iron bisglycinate (25mg elemental) — absorbed via DMT1 (divalent metal transporter 1) on the duodenal brush border; glycinate chelation modestly protects against some competition but does not eliminate it • Calcium citrate (500mg) — absorbed via TRPV6 active transport at low doses and passive paracellular diffusion at higher doses; citrate form is less pH-dependent than carbonate • Vitamin D3 (2000 IU) — fat-soluble, requires bile-salt micelle incorporation for uptake; converted to calcidiol (25-OH-D) by hepatic CYP2R1 • Magnesium glycinate (200mg) — absorbed via TRPM6/TRPM7 channels and passive paracellular routes; competes weakly with other divalent cations • Zinc picolinate (15mg) — absorbed via ZIP4 transporter; among the most transporter-competitive divalent minerals • St. John's Wort / Hypericum perforatum (300mg standardized to 0.3% hypericin) — hyperforin constituent is a potent activator of the nuclear pregnane X receptor (PXR) • Omega-3 fish oil (1000mg, EPA/DHA) — absorbed with dietary fat via micellar solubilization; has a mild, dose-dependent antiplatelet effect • Vitamin K2, menaquinone-7 (100mcg) — fat-soluble, required cofactor for hepatic γ-glutamyl carboxylase activation of clotting factors II, VII, IX, X • Warfarin (5mg, Rx anticoagulant) — narrow therapeutic index drug metabolized by CYP2C9 (S-warfarin, more potent) and CYP1A2/3A4 (R-warfarin); pharmacodynamic target is VKORC1
Four of the nine compounds — iron, calcium, magnesium, and zinc — are all divalent cations competing for an overlapping, saturable pool of intestinal transport machinery. This single structural fact, visible only once the whole stack is profiled together, predicts most of what stage 2 will flag.
With every compound profiled, the checker enumerates all C(9,2) = 36 possible pairs and tests each against three interaction classes recognized by clinical pharmacology: absorption-site competition, hepatic enzyme induction/inhibition, and direct pharmacodynamic antagonism. Seven pairs in this stack return a positive mechanistic flag — a hit rate far higher than most patients or prescribers realize.
Iron, calcium, magnesium, and zinc are all absorbed as divalent cations (Fe2+, Ca2+, Mg2+, Zn2+) in the proximal small intestine, and several of them share or cross-inhibit the same transport machinery:
• Calcium and iron: calcium does not use DMT1 directly, but high luminal Ca2+ interferes with the intracellular signaling and mucosal transfer steps that hand iron from DMT1 to ferroportin, reducing net iron absorption by 30–50% when co-ingested (NIH Office of Dietary Supplements, Iron fact sheet for health professionals). • Zinc and iron: both substrates compete directly for DMT1 affinity; high-dose zinc (>25mg) can reduce non-heme iron absorption by up to 40–50% in single-meal studies. • Calcium and zinc: calcium citrate/carbonate reduces zinc bioavailability roughly 25–30% at typical supplemental doses, likely via luminal complexation and shared paracellular pathways. • Magnesium: the weakest competitor of the four, but additive at high combined doses.
Critically, this is a saturable, competitive-inhibition kinetic — not a fixed percentage. Absorption loss scales with the relative molar excess of the competing cation and is worst when all four are taken as a single simultaneous dose, which is exactly how most multivitamin-plus-mineral routines are structured.
St. John's Wort is the textbook example of herb-drug interaction via nuclear receptor activation rather than direct enzyme inhibition:
• Hyperforin, the bioactive naphthodianthrone-adjacent constituent, is a high-affinity ligand for the pregnane X receptor (PXR), a nuclear receptor that acts as the body's master xenobiotic sensor. • Activated PXR heterodimerizes with RXR and binds response elements upstream of CYP3A4, CYP2C9, and the drug efflux transporter P-glycoprotein (P-gp/ABCB1), upregulating their transcription. • Because this is transcriptional induction (new enzyme protein synthesis), the effect has a delayed onset (7–14 days to reach steady induction) and a delayed offset (1–2 weeks after stopping SJW) — unlike direct inhibition, which is immediate. • CYP3A4 metabolizes an estimated 50% of all marketed small-molecule drugs; induction lowers plasma concentration of oral contraceptives, ciclosporin, HIV protease inhibitors, and — critically for this stack — contributes to warfarin clearance via the minor R-warfarin pathway, while P-gp induction reduces warfarin's effective absorption and tissue exposure.
The vitamin K2–warfarin pair is not a metabolic interaction at all — it is a direct collision at the same molecular target:
• Warfarin works by inhibiting VKORC1 (vitamin K epoxide reductase complex subunit 1), the enzyme that regenerates active vitamin K hydroquinone from its oxidized epoxide form after each use in γ-carboxylation of clotting factors II, VII, IX, and X. • Supplemental vitamin K2 increases the dietary substrate pool available to whatever residual VKORC1 activity remains, partially restoring γ-carboxylation and clotting factor activity — directly opposing warfarin's intended pharmacodynamic effect. • This is dose- and consistency-sensitive: erratic vitamin K intake (starting, stopping, or varying a supplement) is a far more dangerous INR destabilizer than a small but *constant* daily intake, which anticoagulation clinics can actually dose around.
A raw list of seven mechanistic flags is not directly actionable for a patient or a busy prescriber. Interaction-checker platforms — Natural Medicines Comprehensive Database, Stockley's Herbal Interactions, and Lexicomp — condense flags into tiered severity ratings and composite scores so the highest-risk pairs surface first. This simulator implements a simplified version of that scoring logic.
The score displayed in the panel is computed as:
risk = 100 × Σ(severity_i × likelihood_i) / max_possible
Where for each flagged pair i: • severity (1–3): 1 = minor nutrient-absorption dip, 2 = moderate/monitor, 3 = severe/contraindicated-adjacent (bleeding risk, therapeutic failure) • likelihood (0.6–1.0): probability the mechanism manifests clinically given typical dosing and timing, drawn from published interaction literature • max_possible: the theoretical maximum if every pair in the stack were severity-3 at full likelihood
For this stack: three severity-3 pairs (Fe–Ca, SJW–warfarin, K2–warfarin) and two severity-2 pairs (Fe–Zn, Ca–Zn, OM3–warfarin) dominate the score, driving the composite to 68/100 — a "high, action-required" tier under most clinical checker conventions.
Real-world checkers weight additional factors this simplified model omits: renal/hepatic function, age, concurrent conditions (e.g., existing bleeding disorder), and dose relative to labeled maximums.
Three widely used references, each with a distinct methodology:
• Natural Medicines Comprehensive Database — assigns a 5-tier interaction rating (Avoid/Contraindicated, Serious, Moderate, Minor, and Unknown-theoretical), each backed by a graded evidence-quality label (from randomized-controlled-trial-level down to theoretical/case-report-only). • Stockley's Herbal Interactions — the pharmacist reference standard for herb-drug pairs specifically; rates each documented interaction on both clinical significance and strength of supporting evidence, and explicitly documents the St. John's Wort/CYP3A4/P-gp induction pathway as one of the best-characterized herb-drug interactions in the literature. • Lexicomp / UpToDate Interactions — integrates supplement-drug checking into routine EHR-embedded clinical workflow, flagging severity at the point of prescribing so a warfarin order automatically surfaces active herbal/supplement conflicts from the medication list.
All three converge on the same top-line judgment for this stack: the SJW–warfarin and vitamin K2–warfarin pairs both warrant a 'major/avoid-or-monitor-closely' classification, while the divalent-cation competitions are 'moderate — separate dosing' rather than contraindications.
A risk score is a snapshot; the clinical consequence unfolds over days to weeks. This stage simulates three concrete, quantifiable trajectories that a real patient on this exact stack could experience: warfarin plasma exposure falling as CYP3A4/P-gp induction ramps up, serum ferritin drifting downward under chronic same-dose calcium co-administration, and INR (International Normalized Ratio) drifting toward the edge of — or outside — the therapeutic window.
Two independent mechanisms in this stack push warfarin control in opposite directions, which is precisely what makes concurrent use dangerous rather than simply additive:
• St. John's Wort induction lowers warfarin plasma AUC (area under the concentration-time curve) — published case series and pharmacokinetic studies report reductions in the 20–60% range at steady induction, driving INR down and raising clot/thromboembolism risk if the anticoagulant becomes sub-therapeutic. • Vitamin K2 supplementation independently and directly opposes warfarin's pharmacodynamic effect, also pushing INR down but through target-level antagonism rather than clearance. • Omega-3 fish oil at higher doses adds a mild antiplatelet effect that does not move INR itself but layers additional bleeding risk on top of whatever anticoagulation state warfarin achieves — a pharmacodynamic risk invisible to INR monitoring alone.
The net simulated trajectory: INR drifts low (under-anticoagulation, clot risk) while bleeding risk is simultaneously elevated by the omega-3 antiplatelet effect — a genuinely difficult combination to manage without dose titration and closer monitoring.
This is the core danger of stacked interactions: no single pair looks catastrophic in isolation, but the SJW-driven AUC drop, the K2-driven pharmacodynamic antagonism, and the omega-3 antiplatelet effect combine into a patient who is both under-anticoagulated and at elevated bleeding risk at the same time.
Unlike the warfarin interactions, the iron-calcium-zinc competition is a chronic, cumulative nutrient-status problem rather than an acute safety event:
• A single co-administered dose reduces that meal's iron absorption by 30–50%, but the body partially compensates via hepcidin-mediated regulation — the liver-derived peptide hormone that governs ferroportin-mediated iron export from enterocytes and macrophages, upregulating absorption efficiency when body iron stores fall. • Under chronic daily co-dosing, however, this compensation is incomplete: simulated serum ferritin (the primary clinical marker of iron stores) drifts downward roughly 25–35% over 12 weeks in someone with borderline-adequate baseline stores, particularly premenopausal women or anyone with increased iron demand. • The clinical consequence is insidious — fatigue, reduced exercise tolerance, and eventually frank iron-deficiency anemia — that can take months to trace back to a timing problem rather than a dosing problem, since the iron dose itself was never wrong.
Nearly every interaction identified in this stack is manageable without discontinuing a single compound — the dominant fix is timing, not elimination. Separating competing divalent cations by at least two hours restores the large majority of lost absorption, while the warfarin-interacting pairs require a different strategy: consistency, disclosure, and monitoring rather than spacing.
The single highest-leverage fix in this entire stack is procedural, not pharmacological: NIH Office of Dietary Supplements guidance recommends separating iron from calcium-containing supplements or dairy by at least two hours in either direction, and applying the same principle to zinc and magnesium relative to iron and to each other.
A practical revised schedule:
• 7:00 AM (fasting or with a vitamin-C source): iron bisglycinate — maximizes absorption via ascorbate-enhanced non-heme iron uptake, away from all competing cations • 8:00 AM (breakfast, with fat): vitamin D3 + omega-3 fish oil — fat-soluble compounds absorb best co-administered with dietary fat • 1:00 PM (lunch): zinc picolinate — separated from both morning iron and evening calcium/magnesium • 8:00 PM (dinner): calcium citrate + magnesium glycinate — grouped together since calcium-magnesium competition is comparatively minor, and both benefit from evening dosing for sleep-adjacent magnesium effects
Simulated absorption recovery at a 2-hour minimum separation reaches roughly 85–95% of the unimpaired single-compound baseline — most of the lost ground from stage 4 is recoverable through scheduling alone, at zero additional cost.
Timing separation is the rare intervention in clinical pharmacology that is completely free, requires no dose reduction, and eliminates the majority of a real interaction — which is exactly why it is the first-line recommendation in NIH Office of Dietary Supplements fact sheets for iron, calcium, zinc, and magnesium.
Unlike the mineral-competition pairs, the two severity-3 warfarin interactions are not solved by spacing doses across the day, because their mechanisms are systemic (hepatic enzyme induction) or directly pharmacodynamic (clotting-factor synthesis) rather than local to the gut lumen at a given hour:
• St. John's Wort and warfarin: the clinical consensus (reflected in Stockley's Herbal Interactions and most anticoagulation clinic protocols) is to avoid the combination outright, or, if the patient insists on continuing SJW, to increase INR monitoring frequency to weekly during any change in SJW use and expect a warfarin dose increase to compensate for induced clearance — with a repeat INR check 1–2 weeks after stopping SJW as de-induction reverses the effect. • Vitamin K2 and warfarin: the standard anticoagulation-clinic approach is not avoidance but consistency — keeping daily vitamin K intake (dietary plus supplemental) stable so the warfarin dose can be titrated around a fixed baseline, since erratic intake is more dangerous than a steady moderate dose. • Omega-3 fish oil and warfarin: no spacing fix applies to an additive antiplatelet effect; the recommendation is dose awareness (avoid high-dose >3g/day EPA/DHA without physician input) and bleeding-symptom vigilance rather than timing.
The final, optimized regimen therefore combines a scheduling fix (resolves 5 of 7 flags) with an explicit referral: both warfarin-adjacent pairs are escalated for prescriber/pharmacist review rather than resolved by the app alone — reflecting real clinical practice, where consult-a-pharmacist remains the correct endpoint for anything touching a narrow-therapeutic-index drug.